In Memorium

Andrew C. Leon, 1951-2012 (PDF 102Kb)

Andy Leon spent years training new investigators and was generous with his time and wise advice. His intellectual powers were impressive. Yet, when he helped young investigators who were struggling to design a study or interpret statistics, he would gently correct them, never criticizing or humiliating them. He would say, “Well, I have a slightly different take on that and you may want to consider approaching the problem this way”.

Edward G. Jones, 1939-2011 (PDF 192Kb)

Ted Jones distinguished himself in many areas of neuroscience. He was unquestionably the world authority on the Thalamus, producing a remarkable two-volume book filled with his own photomicrographs and illustrations. He was a pioneer of the study of cortico-cortical circuitry and the subpopulations of neurons that comprise local cortical circuits and of neuroplasticity in the cortex and thalamus that helped define the field.

Stephen G. Holtzman, 1944 - 2011 (PDF 167Kb)

Steve Holzman was a pioneer in the use of drug discrimination procedures to investigate the pharmacological properties of opioids. His scientific publications in the 1970s-1990s contributed significantly to the widespread adoption of drug discrimination methodology to study drug-receptor interactions in behaving rodents and non-human primates; this model continues to play a key role in the preclinical development of new drugs for use in psychiatry and drug and alcohol dependence.

Samuel C. Kaim, 1911-2012 (PDF 39Kb)

As the first director of an Alcoholism Service in the US Department of Veterans Affairs, Sam Kaim helped to compel armed forces personnel to recognize the significance of opioid dependence in Vietnam, leading a charge for expansion of his office in 1970 to become the Alcohol and Drug Dependence Services.

Alexander H. Glassman, 1934-2011 (PDF 76Kb)

Dr. Alexander H. Glassman was a pioneer and recognized expert on the impact of psychiatric medication on the heart and the impact of depression on the development of heart disease.

John A. Harvey, 1931-2011 (PDF 87Kb)

John A. Harvey began his long and celebrated career as a faculty member at the University of Chicago. His research career is highlighted by many seminal scientific contributions related to the biochemistry of the brain and the development of behavioral pharmacology.

Alfred M. Freedman, 1917-2011 (PDF 124Kb)

Alfred Freedman was an enthusiastic psychiatric educator and community leader willing to challenge public perceptions and prejudices. He levered the psychiatric world from its self-centered Freudian enthusiasm to caring for the less favored -- the homosexual, the addicted, women, and the imprisoned.

Wayne Fenton, 1953-2006 (PDF 52Kb)

Wayne Fenton, M.D., is best known for his 'behind the scenes' efforts at the NIMH to transform clinical research. In 2003, recognizing the cognitive deficits in schizophrenia and the largest source of disability for many patients, Fenton led landmark NIMH efforts targeting cognitive impairments for people with schizophrenia.

Solomon C. Goldberg, 1924-2007 (PDF 138Kb)

The research career and contributions of Solomon C. Goldberg, Ph.D., helped forge the field of clinical psychopharmacology clinical trials. His expertise in research methodology and statistics are reflected in the statistical techniques that he was often the first to use in clinical psychopharmacology and in the authorship of articles and chapters with biostatisticians.

Louis A. Gottschalk 1916-2008 (PDF 146Kb)

Dr. Gottschalk made national headlines in the late 1980s when he concluded that President Ronald Reagan suffered from cognitive brain impairment as early as his first term, years before the late president was diagnosed with Alzheimer’s.

Jack Peter Green, 1925-2007 (PDF 58Kb)

Jack Peter Green, M.D., Ph.D., was the founding chairperson of the Department of Pharmacology at Mount Sinai School of Medicine and led the department for almost 30 years. Dr. Green was among the first to recognize the multiple subtypes of serotonin receptors in the brain.

Gerard E. Hogarty, 1935-2006 (PDF 51Kb)

Gerard E. Hogarty, M.S.W., is best known for developing four psychosocial treatment approaches specific to schizophrenia.

Murray E. Jarvik, 1923-2008 (PDF 225Kb)

Murray Jarvik was a founding member of ACNP. Murray was best known for his research on nicotine addiction and as a co-inventor of the nicotine patch to help people stop smoking.

Seymour Kaufman, 1924-2009 (PDF 173Kb)

In Dr. Kaufman's five years at New York University, he matured into an outstanding enzymologist and biochemist and made his first major contribution to biochemistry, the discovery of substrate phosphorylation in the conversion of a-ketoglutarate to succinate in the tricarboxylic acid cycle.

Ann E. Kelley, 1954-2007 (PDF 57Kb)

Dr. Ann E. Kelley led an eminent career in which she made groundbreaking contributions to neuropsychopharmacology. Importantly, Dr. Kelley was a pioneer for women in science and launched the successful careers of a generation of neuroscientists through her mentoring and teaching.

Eva King Killam, 1920-2006 (PDF 54Kb)

Eva King Killam, Ph.D., was a founding member of the ACNP and the first female President. Her research focused on the effects and actions of drugs on the brainstem and reticular formation.

Roland Kuhn, 1912-2005 (PDF 55Kb)

Roland Kuhn, M.D., the discoverer in 1956 of the antidepressant effect of imipramine, died October 10, 2005, at the age of 93.

Albert Kurland (PDF 78Kb)

Dr. Albert Kurland was the founder of the Maryland State Psychiatric Research Center and an eternal optimist who worked energetically and never said an unkind word about anyone.